Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EDG 002

Next Previous
X
Search
Drug Profile

EDG 002

Alternative Names: EDG-002

Latest Information Update: 28 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edgewise Therapeutics
  • Class Cardiovascular therapies; Heart failure therapies; Small molecules
  • Mechanism of Action Cardiac myosin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heart failure
  • No development reported Hypertrophic cardiomyopathy

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Hypertrophic-cardiomyopathy in USA
  • 04 Mar 2023 Pharmacodynamics data from a preclinical trial in Hypertrophic cardiomyopathy presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation (ACC-WCC-2023)
  • 01 Mar 2022 Edgewise Therapeutics anticipates selection of the lead candidate from the EDG 002 cardiac muscle programme for inherited hypertrophic cardiomyopathy in the second half of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top